Literature DB >> 23537027

Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine.

Bianca M Arendt1, David W L Ma, Brigitte Simons, Seham A Noureldin, George Therapondos, Maha Guindi, Morris Sherman, Johane P Allard.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with altered hepatic lipid composition. Animal studies suggest that the hepatic ratio of phosphatidylcholine (PC) to phosphatidylethanolamine (PE) contributes to steatogenesis and inflammation. This ratio may be influenced by dysregulation of the PE N-methyltransferase (PEMT) pathway or by a low-choline diet. Alterations in the liver may also influence lipid composition in circulation such as in erythrocytes, which therefore may have utility as a biomarker of hepatic disease. Currently, no study has assessed both liver and erythrocyte PC/PE ratios in NAFLD. The aim of this study was to compare the PC/PE ratio in the liver and erythrocytes of patients with simple steatosis (SS) or nonalcoholic steatohepatitis (NASH) with that of healthy controls. PC and PE were measured by mass spectrometry in 28 patients with biopsy-proven NAFLD (14 SS, 14 NASH) and 9 healthy living liver donors as controls. The hepatic PC/PE ratio was lower in SS patients (median [range]) (1.23 [0.27-3.40]) and NASH patients (1.29 [0.77-3.22]) compared with controls (3.14 [2.20-3.73]); both p < 0.001) but it was not different between SS and NASH. PC was lower and PE higher in the liver of SS patients compared with controls, whereas in NASH patients only PE was higher. The PC/PE ratio in erythrocytes was also lower in SS and NASH patients compared with controls because of lower PC in both patient groups. PE in erythrocytes was not different among the groups. In conclusion, NAFLD patients have a lower PC/PE ratio in the liver and erythrocytes than do healthy controls, which may play a role in the pathogenesis. The underlying mechanisms require further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23537027     DOI: 10.1139/apnm-2012-0261

Source DB:  PubMed          Journal:  Appl Physiol Nutr Metab        ISSN: 1715-5312            Impact factor:   2.665


  43 in total

1.  Plasma lipidome patterns associated with cardiovascular risk in the PREDIMED trial: A case-cohort study.

Authors:  Cristina Razquin; Liming Liang; Estefanía Toledo; Clary B Clish; Miguel Ruiz-Canela; Yan Zheng; Dong D Wang; Dolores Corella; Olga Castaner; Emilio Ros; Fernando Aros; Enrique Gomez-Gracia; Miquel Fiol; José Manuel Santos-Lozano; Marta Guasch-Ferre; Lluis Serra-Majem; Aleix Sala-Vila; Pilar Buil-Cosiales; Monica Bullo; Montserrat Fito; Olga Portoles; Ramon Estruch; Jordi Salas-Salvado; Frank B Hu; Miguel A Martinez-Gonzalez
Journal:  Int J Cardiol       Date:  2018-02-15       Impact factor: 4.164

2.  Red Blood Cell Dysfunction in Non-Alcoholic Fatty Liver Disease: Marker and Mediator of Molecular Mechanisms.

Authors:  Charalampos Papadopoulos; Ioannis Tentes; Konstantinos Anagnostopoulos
Journal:  Maedica (Bucur)       Date:  2020-12

Review 3.  Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.

Authors:  Eric K Kwong; Puneet Puri
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

Review 4.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

5.  Lipidomics unveils lipid dyshomeostasis and low circulating plasmalogens as biomarkers in a monogenic mitochondrial disorder.

Authors:  Matthieu Ruiz; Alexanne Cuillerier; Caroline Daneault; Sonia Deschênes; Isabelle Robillard Frayne; Bertrand Bouchard; Anik Forest; Julie Thompson Legault; Frederic M Vaz; John D Rioux; Yan Burelle; Christine Des Rosiers
Journal:  JCI Insight       Date:  2019-07-25

6.  Publisher Correction: The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

7.  Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial.

Authors:  Cristina Razquin; Estefanía Toledo; Clary B Clish; Miguel Ruiz-Canela; Courtney Dennis; Dolores Corella; Christopher Papandreou; Emilio Ros; Ramon Estruch; Marta Guasch-Ferré; Enrique Gómez-Gracia; Montserrat Fitó; Edward Yu; José Lapetra; Dong Wang; Dora Romaguera; Liming Liang; Angel Alonso-Gómez; Amy Deik; Mónica Bullo; Lluis Serra-Majem; Jordi Salas-Salvadó; Frank B Hu; Miguel A Martínez-González
Journal:  Diabetes Care       Date:  2018-10-16       Impact factor: 19.112

Review 8.  Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.

Authors:  Peter J Meikle; Scott A Summers
Journal:  Nat Rev Endocrinol       Date:  2016-10-21       Impact factor: 43.330

9.  Cholesterol and Phospholipid Distribution Pattern in the Erythrocyte Membrane of Patients with Hepatitis C and Severe Fibrosis, before and after Treatment with Direct Antiviral Agents: A pilot Study.

Authors:  Charalampos Papadopoulos; Maria Panopoulou; Theodora Mylopoulou; Konstantinos Mimidis; Ioannis Tentes; Konstantinos Anagnostopoulos
Journal:  Maedica (Bucur)       Date:  2020-06

10.  Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese.

Authors:  Puneet Puri; Jun Xu; Terhi Vihervaara; Riikka Katainen; Kim Ekroos; Kalyani Daita; Hae-Ki Min; Andrew Joyce; Faridoddin Mirshahi; Hidekazu Tsukamoto; Arun J Sanyal
Journal:  J Lipid Res       Date:  2016-03-28       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.